摘要
目的:为埃克替尼治疗晚期非小细胞肺癌的医保报销政策制定提供量化参考。方法:通过构建预算影响分析模型,比较国家医保目录内的化疗方案,预测未来5年埃克替尼进入目录后对医保基金预算的影响。结果:将埃克替尼及其相关靶向治疗的基因检测费用纳入医保目录,晚期非小细胞肺癌患者2017—2021年医保费用预算支出降幅为-0.15%,-0.14%,-0.12%,-0.10%及-0.08%。结论:建议各地区结合医保基金收支情况设置合理报销政策,将埃克替尼纳入医保目录。
Objective： To provide a quantitative reference of making medical insurance reimbursement policies about icotinib for treating terminal non-small cell lung cancer(NSCLC）. Methods： Budget impact analysis model was constructed to compare the chemotherapy treatment scheme in national medical insurance directory,and measure the expected changes in the expenditure of medical insurance funds in the next five years. Results： If icotinib and genetic testing costs of targeted treatment could be reimbursed,the reduction of medical insurance budget on terminal NSCLC patient would be-0. 15%,-0. 14%,-0. 12%,-0. 10% and-0. 08% from 2017 to 2021. Conclusion：This study recommends that all regions should set up reasonable reimbursement policies according to the balance of payments for medical insurance fund,and bring icotinib into the medical insurance directory.
作者
罗雪燕
袁泉
姚文兵
LUO Xue-yan;YUAN Quan;YAO Wen-bing(School of Biological and Chemical Engineering, Chongqing University of Education, Chongqing 400067, China;School of International Parmaceutical Business, China Parmaceutical University, Nanjing 211198, China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2018年第9期973-977,共5页
Chinese Journal of New Drugs
基金
重庆市教委2015年度科学技术研究项目(KJ1501417)
关键词
非小细胞肺癌
埃克替尼
预算影响分析
non-small cell lung cancer （NSCLC）
icotinib
budget impact analysis
